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A 57-year-old woman was referred for dyspnoea during mild exercise, especially during
the past year. Electrocardiogram and chest X-ray demonstrated no signiﬁcant anomaly. Nt-
pro brain natriuretic peptide was moderately elevated to 319 ng/L (range: 0—290 ng/L).
Echocardiographic examination showed normal left ventricle function and anatomy, mild
regurgitations of the aortic and mitral valves and a severe regurgitation of the tricuspid
valve (Figs. 1 and 2), with an estimated systolic pulmonary pressure of 60mmHg. The mech-
anism of the valvular regurgitations corresponded to valvular ﬁbrosis and subsequently
restriction motion. Right heart catheterization conﬁrmed pulmonary arterial hypertension
with normal pulmonary wedge pressure and cardiac output. Thoracic tomodensitometry
ruled out pulmonary embolism. There was also no clinical or biological evidence for a
carcinoid syndrome. The patient had no previous medical history, but she had taken ben-
ﬂuorex (150mg tid) for the past 8 years because of excessive weight (159 cm, 82 kg) and
hypertriglyceridaemia.
In addition to withdrawal of the drug, and because of elevated right atrial pressure, weHypertension
valvulaire ;
Effets secondaires
médicamenteux
started furosemide 40mg per day but no speciﬁc treatment was given for pulmonary artery
hypertension. Three months later, echocardiography showed consistently severe tricuspid
regurgitation with an estimated systolic pulmonary pressure of 50mmHg. No other right
heart catheterization was done, in accordance with the patient’s wishes, as she felt better
and had dyspnoea class II in the New York Heart Association classiﬁcation.
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Figure 1. Transthoracic echocardiography (apical 4-chamber
plane) showing (A) dilatation of the right cavities, ﬁbrosis of the tri-
cuspid valves responsible for a hiatus during systole and (B) severe
tricuspid regurgitation in colour Doppler. RA: right atrium; RV: right
ventricle; LA: left atrium; LV: left ventricle.Figure 2. Transthoracic echocardiography (apical 4-chamber
plane) showing continuous Doppler of tricuspid insufﬁciency.
Fenﬂuramine-derivative diet pills were withdrawn from
the market in 1997 because of an association with valvu-
lar regurgitation and pulmonary hypertension. The similarity
of the echocardiographic lesions observed in our patient
with those reported with fenﬂuramine makes us discuss the
imputability of benﬂuorex, which is structurally related to
other amphetamines.
This observation underlines a potentially underesti-
mated adverse drug reaction with benﬂuorex of which
every cardiologist should be aware. Additionally, since
this ﬁrst observation we have seen two other cases of
severe tricuspid
in patients onplurivalvular regurgitation (in particular
insufﬁciency) and pulmonary hypertension
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